Alliance A032103: MODERN study for bladder cancer - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if a medical technology called the Signatera blood test can help doctors and patients determine the best course of treatment for bladder cancer after the patient has a radical cystectomy (removal of the bladder and surrounding lymph nodes). The Signatera test is used to detect cancer DNA in the blood before cancer can be seen using imaging (like MRI or CT scans).
Cáncer de vejiga
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with urothelial cancer of the bladder
- Had a radical cystectomy (RC) surgery at least 3 weeks, but no more than 12 weeks, before joining the study
- Have no evidence of remaining disease after RC surgery
- Have not had any postoperative/adjuvant systemic therapy or radiation
- Have never been treated with any PD-1 or PD-L1 axis inhibitors
For more information, contact the study team at nick.jeffries@duke.edu.
¿Qué Implica?
This study wants to find out if a blood test can help doctors make better choices about who should get immunotherapy after bladder cancer surgery and which treatment is the best. DNA is the material inside every cell that tells the cell how to work. Cancer cells often have DNA that looks different from normal DNA. New tests can find bladder cancer DNA in the blood, which may show that cancer cells are still in the body. Researchers want to see if this information can help guide treatment after the bladder is removed.
Detalles del Estudio
